Stocks Health care IRWD
NASDAQ · Health careIronwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals Inc brought in $400.3M of revenue over the twelve months to September 30, 2026, up 18.1% from a year earlier. Net income was $149.6M, a net margin of 37.4%. Operating cash flow minus capital spending left $127M of free cash flow in fiscal 2025. At September 30, 2026 it held $86.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Ironwood Pharmaceuticals Inc
- Net worth
- Ironwood Pharmaceuticals Inc has a market value (market cap) of $801.4M at the latest share price, and shareholders' equity of -$97.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $296.2M (-15.7% year on year), with net income of $24M. Over the 12 months to September 30, 2026: revenue $400.3M, net income $149.6M.
- Cash flow
- In fiscal 2025 operations brought in $127M of cash; after $34K of capital spending, free cash flow was $127M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ironwood Pharmaceuticals Inc's next report is expected around January 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ironwood Pharmaceuticals Inc does
Ironwood Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IRWD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $296.2M | $24M | $0.15 | $127M |
| 2024 | $351.4M | $880K | $0.01 | $103.4M |
| 2023 | $442.7M | -$1B | -$6.45 | $183.2M |
| 2022 | $410.6M | $175.1M | $0.96 | $273.6M |
| 2021 | $413.8M | $528.4M | $3.21 | $261.6M |
| 2020 | $389.5M | $106.2M | $0.66 | $167M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IRWD ranks in Health care
Latest SEC filings
What Ironwood Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 9% to $133M versus the same quarter last year; diluted EPS $0.36 versus $0.23.
- November 5, 2026
- October 28, 2026Passive stake changed SCHEDULE 13G/A
- October 16, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 33% to $113M versus the same quarter last year; diluted EPS $0.31 versus $0.14.
- August 6, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
What is IRWD worth? A DCF from its reported cash flow
Insider trades
What the people running Ironwood Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Denner Alexander JDirector | Received as pay | 3,694 | - |
| July 20, 2026 | Silber JeffreySVP, CMO, Head-Res&Drug | Received as pay | 137,036 | - |
| July 7, 2026 | Silver RonaldPFO & PAO | Soldpre-planned (10b5-1) | 127,890 | $578.1K |
| June 16, 2026 | Moukheibir CatherineDirector | Received as pay | 63,481 | - |
| June 16, 2026 | McHugh JulieDirector | Received as pay | 63,481 | - |
| June 16, 2026 | McHugh JulieDirector | Soldpre-planned (10b5-1) | 21,571 | $80.5K |
| June 16, 2026 | Denner Alexander JDirector | Received as pay | 63,481 | - |
| June 16, 2026 | Duane Jon RDirector | Received as pay | 63,481 | - |
Who owns IRWD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 8.43% | August 14, 2026 |
| Alexander J. Denner13D, may seek influence with 1 related filers | 5.8% | March 19, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 212 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 17,788,557 | +4,425,627 |
| Armistice Capital, LLC | 13,932,000 | -1,096,000 |
| Sarissa Capital Management LP | 9,188,635 | 0 |
| State Street Corp | 8,809,601 | +1,352,657 |
| Bank of America Corp | 8,683,803 | +896 |
| Renaissance Technologies LLC | 7,993,226 | -67,847 |
| Vanguard Capital Management LLC | 6,608,508 | +511,054 |
| Aqr Capital Management LLC | 6,465,921 | -1,069,159 |
| Vanguard Portfolio Management LLC | 5,513,355 | -1,168,682 |
| Geode Capital Management, LLC | 4,831,657 | +288,135 |
| Two Sigma Investments, LP | 4,556,089 | -1,292,187 |
| Marshall Wace, Llp | 4,290,093 | -234,971 |
| Jacobs Levy Equity Management, Inc | 4,065,964 | +433,487 |
| Goldman Sachs Group Inc | 3,313,808 | +623,174 |
| Charles Schwab Investment Management Inc | 3,302,242 | -1,435,615 |
| Federated Hermes, Inc. | 3,231,238 | -117,568 |
| Arrowstreet Capital, Limited Partnership | 3,017,089 | -380,153 |
| Dimensional Fund Advisors LP | 2,522,891 | +440,836 |
| Mackenzie Financial Corp | 2,367,493 | +1,807,459 |
| Morgan Stanley | 1,859,914 | +1,035,095 |
Insiders
14 insiders reported holding 16,462,125 shares in total, about $79.8M at the last price.
| Holder | Shares |
|---|---|
| Denner Alexander JDirector | 9,516,1849,188,635 held indirectly |
| MCCOURT Thomas AChief Executive Officer, Director | 1,898,838 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | 1,179,462 |
| Silver RonaldPFO & PAO | 755,250 |
| Currie Mark GDirector | 676,900 |
| John MinardoChief Legal Officer | 500,498 |
| Gaskins Tammi LChief Commercial Officer | 350,350 |
| Martini Gregory S.Chief Financial Officer | 297,213 |
| Duane Jon RDirector | 253,820 |
| McHugh JulieDirector | 250,749 |
Questions about IRWD
What does Ironwood Pharmaceuticals Inc do?
Ironwood Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as IRWD. Its shares trade on NASDAQ under the ticker IRWD.
What is Ironwood Pharmaceuticals Inc's net worth?
Ironwood Pharmaceuticals Inc has a market value (market cap) of $801.4M at the latest share price, and shareholders' equity of -$97.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ironwood Pharmaceuticals Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $149.6M on revenue of $400.3M, a net margin of 37.4%.
How much revenue does Ironwood Pharmaceuticals Inc make?
Over the twelve months to September 30, 2026 Ironwood Pharmaceuticals Inc reported revenue of $400.3M. That is 18.1% more than a year earlier.
When did Ironwood Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Ironwood Pharmaceuticals Inc's next earnings report?
Ironwood Pharmaceuticals Inc's next report is expected around January 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IRWD with
Follow IRWD
Get an email when Ironwood Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ironwood Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.